Andrew Bradbury Attends Antibody Engineering & Therapeutics Conference
Specifica Founder & CSO, Andrew Bradbury, recently attended the Antibody Engineering & Therapeutics Conference, the #1 antibody engineering conference for accelerating the next generation antibodies for commercial success.
This virtual event was held December 14-15, 2020 for attendees to share and discover the latest science, technology and partners in antibody engineering, immunobiology and next generation binders. This conference included over 1,000 attendees from leading pharma, biotech, and academia from around the globe.
While attending the conference, Bradbury and other industry leaders presented sessions on “Antibody Selection and Screening in Early Discovery” and “Drug-like Antibodies Straight from Selections”.
To learn more and see a full presentation of Dr. Bradbury’s webinar see: https://www.specifica.bio/
Andrew Bradbury is Chief Scientific Officer of Specifica, a company he founded in 2016, after retiring as Group Leader at LANL. He trained in medicine at the Universities of Oxford and London and received his PhD from the University of Cambridge at the MRC Laboratory of Molecular Biology, under the guidance of Cesar Milstein. He has worked in antibody engineering for over thirty years. Specifica’s mission is to provide companies developing therapeutic antibodies with the world’s best antibody selection platform
The New Mexico Consortium is proud to be a supporter of Specifica, a New Mexico company revolutionizing antibody discovery.